Alaunos Therapeutics, Inc. (TCRT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Alaunos Therapeutics reported revenue of $5,000, down 50.0% from $10,000 the year before. Net income was -$4.2M (a -83520.0% net margin), or -$2.20 per diluted share. Operating margin was -84500.0%. Operating activities generated -$2.9M of cash, leaving -$3.0M of free cash flow. At fiscal year end, Alaunos Therapeutics held $3.0M in total assets against $813,000 in total liabilities, including $1.4M of cash and equivalents.
Open the full interactive Alaunos Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Alaunos Therapeutics Key Stats
| Share Price | $3.03 |
|---|---|
| Market Cap | $7.4M |
| Revenue YoY Growth | -50.0% |
| 52-Week Range | $0.74 – $4.36 |
| Shares Outstanding | 2.4 million (basic, 2026 Q2) |
Alaunos Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $398,000 | $2.9M | $5,000 | $10,000 | $5,000 |
| Operating Income | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.8M | -$4.2M |
| Pre-Tax Income | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| Diluted EPS | -$57.00 | -$55.50 | -$25.50 | -$22.00 | -$2.92 | -$2.20 |
Alaunos Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $3,000 | $0 | $0 |
| Net Income | -$1.2M | -$893,000 | -$1.0M | -$952,000 |
| Diluted EPS | -$0.55 | -$0.46 | -$0.59 | -$0.41 |
Alaunos Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $115.1M | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M |
| Current Assets | $130.6M | $78.8M | $53.8M | $8.3M | $2.8M | $2.0M |
| Total Assets | $146.3M | $94.9M | $64.9M | $8.3M | $2.8M | $3.0M |
| Current Liabilities | $18.4M | $16.0M | $24.2M | $2.0M | $692,000 | $813,000 |
| Total Long-Term Debt | — | $24.1M | $16.8M | — | — | — |
| Total Liabilities | $22.4M | $36.8M | $26.4M | $2.0M | $692,000 | $813,000 |
| Shareholders' Equity | $124.0M | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M |
Alaunos Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$57.0M | -$61.5M | -$29.2M | -$30.1M | -$5.0M | -$2.9M |
| Cash From Investing | -$9.8M | -$3.3M | -$193,000 | $1.3M | $0 | -$98,000 |
| Cash From Financing | $102.1M | $25.8M | $6.4M | -$18.1M | $0 | $3.3M |
| Free Cash Flow | -$66.8M | -$64.8M | -$29.4M | -$30.3M | -$5.0M | -$3.0M |
Figures from Alaunos Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alaunos Therapeutics financials page for every line item.
Alaunos Therapeutics Company Profile
| Ticker | TCRT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Fort Lauderdale, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001107421 |
Frequently Asked Questions
What was Alaunos Therapeutics' revenue in fiscal 2025?
Alaunos Therapeutics (TCRT) reported revenue of $5,000 for fiscal 2025.
What is Alaunos Therapeutics' annual revenue history?
Alaunos Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $398,000; 2022: $2.9M; 2023: $5,000; 2024: $10,000; 2025: $5,000.
What was Alaunos Therapeutics' net income in fiscal 2025?
Alaunos Therapeutics reported net income of -$4.2M for fiscal 2025.
What was Alaunos Therapeutics' earnings per share (EPS) in fiscal 2025?
Alaunos Therapeutics' diluted EPS was -$2.20 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alaunos Therapeutics generate in fiscal 2025?
Alaunos Therapeutics generated -$3.0M of free cash flow in fiscal 2025.
What was Alaunos Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Alaunos Therapeutics reported revenue of $0.
How many shares of Alaunos Therapeutics are outstanding?
Alaunos Therapeutics reported a weighted average of 2.4 million basic shares outstanding in 2026 Q2.
What is Alaunos Therapeutics' market cap?
Based on its latest closing price, Alaunos Therapeutics (TCRT) has a market capitalization of about $7.4M.
When does Alaunos Therapeutics' fiscal year end?
Alaunos Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Alaunos Therapeutics headquartered?
Alaunos Therapeutics lists its business address in Fort Lauderdale, Florida in its SEC filings.